Photobiomodulation in Salivary Production of Patients With Xerostomy
NCT03632096 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2018-10-11
Summary
Xerostomia is a quantitative and qualitative alteration of saliva, a symptom present in individuals who make continuous use of medications to control chronic diseases, including hypertension. Difficulties in mastication, swallowing, phonation and palate are present, besides oral burning syndrome, periodontal disease, root caries and bad breath that will interfere in the quality of life, making it difficult to socialize in society. Currently, the methods presented for treatment of xerostomia are palliative, so their use does not consist of an effective treatment. The objective of this study is to evaluate the efficacy of photobiomodulation in the production of saliva in patients with xerostomia induced by antihypertensive drugs. The method consists in the application of the low intensity laser in the three pairs of salivary glands - parotid, submandibular and sublingual. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The control group will have a simulation of the application of the laser, with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off. In the group that receives the photobiomodulation the device will have its timer turned off, to avoid the perception of sound difference. At the end of the sessions, a sample of saliva will be collected, which will be compared to the initial sample.
Conditions
- Xerostomia
Interventions
- RADIATION
-
Photobiomodulation
The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
- RADIATION
-
Sham
The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
Sponsors & Collaborators
-
University of Nove de Julho
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-10
- Primary Completion
- 2018-12-10
- Completion
- 2018-12-30
Countries
- Brazil
Study Locations
More Related Trials
-
Effects of Photobiomodulation in Salivary Analysis of Chronic Renal Failure Patients
NCT03647813 ·Status: COMPLETED ·Phase: PHASE2
-
Beneficial Effects of Natural Products on Management of Xerostomia
NCT06217614 ·Status: COMPLETED ·Phase: NA
-
The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study
NCT01754740 ·Status: COMPLETED ·Phase: NA
-
Interest of the Sialendoscopy Associated With a Local Injection of Corticosteroids in the Treatment of Radio-induced Xerostomia in Comparison With the Hygiene Rules
NCT04584164 ·Status: RECRUITING ·Phase: NA
-
Photobiomodulation In Treatment Of Xerostomia In Type Ii Diabetic Patients
NCT06703372 ·Status: COMPLETED ·Phase: NA
-
Salivary Markers in Patients With Xerostomia
NCT03156569 ·Status: COMPLETED
-
Diagnostic Interest of the Buccal Schirmer Test in Xerostomia During Sjögren's Syndrome: XERODIAG
NCT06530940 ·Status: NOT_YET_RECRUITING
-
Effect of 0.1% Pilocarpine Mouthwash on Xerostomia
NCT01627626 ·Status: COMPLETED ·Phase: NA
-
Salivary Flow Rate and Oral Function
NCT01020084 ·Status: COMPLETED
-
Quality of Life and Sjögren Syndrome
NCT03578900 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study New Gel for Xerostomia
NCT04184908 ·Status: UNKNOWN ·Phase: PHASE1
-
Topical Management of Xerostomia With Dry Mouth Products
NCT03611283 ·Status: COMPLETED ·Phase: NA
-
Effect to the Photobiomodulation in the Burning Mouth Syndrome
NCT05871580 ·Status: COMPLETED ·Phase: NA
-
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
NCT03530735 ·Status: UNKNOWN ·Phase: NA
-
CLINICAL EVALUATION OF THE EFFICACY OF AN INTRA ORAL SPRAY FOR PATIENTS WITH XEROSTOMIA
NCT04719091 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
NCT00332618 ·Status: COMPLETED
-
Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
NCT01690052 ·Status: COMPLETED ·Phase: NA
-
Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related Quality of Life in Older Patients
NCT06984848 ·Status: RECRUITING ·Phase: NA
-
Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
NCT02641912 ·Status: COMPLETED ·Phase: NA
-
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients
NCT00873496 ·Status: COMPLETED
-
the Effect of Mixture of Natural Products As Salivary Substitutes in Treatment Of Xerostomia
NCT04252209 ·Status: COMPLETED ·Phase: PHASE3
-
Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
NCT01652001 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
This Present Study Can be Used by Clinicians Who Treat Psychiatric Patients: Dentists Might Expect Xerogenic Side Effects of Specific Psychiatric Drugs Which Can Affect Dental Treatment, and the Results Can Help Psychiatrist to Choose the Less Xerogenic Psychiatric Medication
NCT06920472 ·Status: COMPLETED
-
Tolerance and Efficiency of an Intrabuccal Biological Film to Enhance Oral Dryness Sensation: The "PREDELFI" Clinical Pilot Study
NCT04206826 ·Status: COMPLETED ·Phase: NA
-
Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome
NCT00637793 ·Status: COMPLETED ·Phase: PHASE2